Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma

Bone marrow (BM) assessment of minimal residual disease (MRD) is prognostic for survival in multiple myeloma (MM). BM is still hypocellular at month 1 post CAR-T, thus the value of MRD negative (MRDneg) status at this timepoint is unclear. We examined the impact of month 1 BM MRD status in MM patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Bansal, Radhika, Baksh, Mizba, Larsen, Jeremy T., Hathcock, Matthew A., Dingli, David, Stewart, A. Keith, Kapoor, Prashant, Kourelis, Taxiarchis, Hayman, Suzanne R., Warsame, Rahma M., Fonseca, Rafael, Bergsagel, P. Leif, Ailawadhi, Sikander, Kumar, Shaji K., Lin, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076306/
https://www.ncbi.nlm.nih.gov/pubmed/37019896
http://dx.doi.org/10.1038/s41408-023-00820-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076306/
https://www.ncbi.nlm.nih.gov/pubmed/37019896
http://dx.doi.org/10.1038/s41408-023-00820-y

Ejemplares similares